In part I of our comprehensive report on the type II diabetes market, we broke down the top 4 best selling diabetes drugs, their prospects and the companies behind them.
Keep Reading →
June 27 - News, Stock Analysis
At the turn of the millennium, the population of the United States clocked in at 282.2 million.
Keep Reading →
June 22 - News, Stock Analysis
Founded in 1982 by James ‘Jim’ Simons, Renaissance Technologies employs quantitative models based on mathematical and statistical analysis to make its stock selections and...
Keep Reading →
May 18 - Hedge Fund Analysis, Hedge Funds, News
Is Novo Nordisk A/S (ADR) (NYSE:NVO) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research.
Keep Reading →
November 30 - Hedge Funds, News
Well-known hedge fund Renaissance Technologies LLC needs little or no introduction at all.
Keep Reading →
November 14 - Hedge Fund Analysis, Hedge Funds, News
Arrowstreet Capital is a Boston, Massachusetts-based quantitative hedge fund founded by Peter Rathjens, Bruce Clarke and John Campbell in 1999.
Keep Reading →
November 11 - Hedge Fund Analysis, Hedge Funds, News
At the beginning of September, when the U.S stock markets were in turmoil, Ken Fisher of Fisher Asset Management asserted that the August correction would be “over just as fast...
Keep Reading →
November 3 - Hedge Fund Analysis, Hedge Funds, News
On October 15, Emisphere Technologies Inc.
Keep Reading →
October 16 - Hedge Funds, Market Movers, News
Renaissance Technologies, led by Jim Simons, disclosed a total of 3,196 positions in its latest 13F filing for the reporting period of June 30.
Keep Reading →
October 8 - Hedge Fund Analysis, Hedge Funds, News
Novo Nordisk A/S (ADR) (NYSE:NVO) and Sanofi SA (ADR) (NYSE:SNY) are two healthcare companies that recently received product approval in the US and Europe, respectively, but both...
Keep Reading →
September 28 - Market Movers, News
Renaissance Technologies, founded by billionaire Jim Simons, has filed its latest 13F with the U.S.
Keep Reading →
May 17 - Hedge Funds, News
Tom Gayner’s Markel Gayner Asset Management, the investment division of financial holding company Markel Corporation (NYSE:MKL), has filed its latest 13F with the Securities...
Keep Reading →
May 14 - Hedge Funds, News
As we are entering into the second quarter of 2015, it's time to take a brief look back and see how the market performed during the first three months of the year, and most importantly...
Keep Reading →
April 1 - Hedge Funds, News, Tech
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other...
Keep Reading →
March 27 - Hedge Funds, News
Another major hedge fund that recently disclosed its long equity positions for the second quarter of 2014 is Jim Simons’ Renaissance Technologies, one of the best performing...
Keep Reading →
August 14 - Hedge Funds
In the latest 13F, Renaissance Technologies, previously managed by Jim Simons, revealed its holding for the fourth quarter of 2013.
Keep Reading →
February 14 - Hedge Funds, News
This is close to the market cap that Bank of America's Steve Byrne thinks MannKind Corporation (NASDAQ:MNKD) is worth.
Keep Reading →
September 17 - News
Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends.
Keep Reading →
September 16 - Dividend Stocks, News
In pharmacology, we don't only have to consider the actions of the drug on the body.
Keep Reading →
September 12 - News
Express Scripts Holding Company (NASDAQ:ESRX) -- the largest pharmacy benefit manager, or PBM, in America -- is also one of the most important companies in the health care ...
Keep Reading →
September 11 - News
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to track Mr. Market.
Keep Reading →
September 5 - News
The drug more closely mimics how the body secretes insulin after a meal to lower blood sugar, doing its job and leaving the bloodstream quickly.
Keep Reading →
September 2 - News
The idea inspired me to issue my own questions about the company, using the questions as a crutch to explain my position.
Keep Reading →
August 28 - News
In the eyes of many of your fellow readers, hedge funds are seen as useless, old financial vehicles of an era lost to time.
Keep Reading →
August 26 - News
The orthopedic implants market is a growing segment with increasing demand for extremities, spine, and orthobiologics.
Keep Reading →
August 22 - News
Like most pharma companies, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s stock price generally trades akin to the actions of a roller coaster.
Keep Reading →
August 22 - News
At least the Food and Drug Administration is polite.
Keep Reading →
August 19 - News
MannKind Corporation (NASDAQ:MNKD) ended up more than 10% on Wednesday, after the biotech announced positive results for two phase 3 trials testing its inhaled insulin Afrezza...
Keep Reading →
August 15 - News
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive.
Keep Reading →
August 12 - News
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 12 - News
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Keep Reading →
August 12 - News
The sales come from less than a month on the market -- the drug launched on June 11 and the quarter closed on June 30 -- and can't tell you anything about the long-term potential...
Keep Reading →
August 2 - News
Diabetes is one of the world's most dangerous and fastest-growing afflictions.
Keep Reading →
August 1 - News
Arena Pharmaceuticals, Inc.
Keep Reading →
July 31 - News
It's been a long time since China's double-digit economic growth became the envy of nations across the world. Since then, the Chinese economy has slowed.
Keep Reading →
July 29 - News
NutriSystem Inc. (NASDAQ:NTRI), Novo Nordisk A/S (ADR) (NYSE:NVO), and Universal Health Services, Inc.
Keep Reading →
July 26 - News
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs...
Keep Reading →
July 18 - News
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 12 - News
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Keep Reading →
July 10 - News
However you feel about celebrity chef Paula Deen, it's hard to ignore the impact one person has on the business world.
Keep Reading →
July 5 - News
Merck & Co., Inc. (NYSE:MRK) has had its fair share of bad news recently. Shares have pulled back around 5% in June.
Keep Reading →
July 1 - News
The trickle has become a torrent.
Keep Reading →
June 28 - News
It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide.
Keep Reading →
June 28 - News
After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly & Co. (NYSE:LLY) finally has some good news to report.
Keep Reading →
June 27 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
Keep Reading →
June 18 - News
Everyone loves a defensive growth story, and there aren’t many better companies in the category than The Cooper Companies, Inc. (NYSE:COO).
Keep Reading →
June 12 - News
It was only a matter of time.
Keep Reading →
June 7 - News
Novo Nordisk A/S (ADR) (NYSE:NVO) was in 13 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 6 - News
The field of synthetic biology is still in its infancy, with many of the most promising companies residing outside of public markets, but make no mistake: The bioeconomy is on...
Keep Reading →
May 31 - News
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc.
Keep Reading →
May 28 - News